494
Participants
Start Date
October 2, 2023
Primary Completion Date
March 31, 2025
Study Completion Date
December 31, 2025
Adalimumab
Adalimumab injection 40 mg / 0.8 ml
Humira
Adalimumab injection 40 mg / 0.4 ml
RECRUITING
Regional dermatovenerologic dispensary, Barnaul
RECRUITING
Chelyabinsk Regional Clinical Dermatovenerologic Dispensary, Chelyabinsk
NOT_YET_RECRUITING
Interregional Clinical Diagnostic Center, Kazan'
NOT_YET_RECRUITING
City clinical hospital n.a.Botkin, Moscow
NOT_YET_RECRUITING
Rheumatology research Instititue n.a.Nasonova, Moscow
NOT_YET_RECRUITING
State Scientific Center of Dermatovenerology and Cosmetology, Nizhny Novgorod
NOT_YET_RECRUITING
Reafan, Novosibirsk
NOT_YET_RECRUITING
New Clinic, Pyatigorsk
NOT_YET_RECRUITING
Dermatovenerologic dispensary N10, Saint Petersburg
Mabscale, LLC
INDUSTRY